Stocks
Wells Fargo Raises Merck Price Target to $170
Wells Fargo has maintained its 'buy' rating on Merck & Co (MRK.US), a multinational pharmaceutical company. Analyst Mohit Bansal upgraded the target price from $150 to $170, citing potential growth in the sector.
Bansal's success rate is 62.2%, with an average return of 12.3% over the past year, according to TipRanks data.
The analyst's performance has been evaluated by TipRanks, which provides analysis data from financial analysts and calculates their average returns and success rates.